Mavenir’s Converged Packet Core to power Deutsche Telekom’s 5G standalone (SA) network in Germany
Deutsche Telekom andMavenir announced the successful delivery and deployment of cloud-native 5G Core to Deutsche Telekom in Germany. Deutsche Telekom selected Mavenir as the supplier for software applications to run on its defined hardware and the existing Kubernetes-based platform of its German business, ensuring an open architecture approach. As part of the deployment process, the Converged Packet Core was integrated with Telekom’s existing multi-vendor access network and other system components.
The new Converged Packet Core supports data, voice, and messaging services and network slicing. The initial network slicing use case is focused on live video broadcasting. The deployment has been successfully certified against devices from the major terminal vendors.
The Mavenir solution is based on automated software delivery and network upgrades. This will allow new Converged Packet Core services with all the required network functions to be deployed in minutes by using the automation framework of Deutsche Telekom. It is largely self-updating for the entire lifecycle of each application. The platform can automatically synchronize production environment resources and configuration with changes expressed in code. It is therefore less prone to the human errors that come with manual testing and deployment.
Dr. Abdurazak Mudesir, Group CTO Deutsche Telekom, said: “The deployment of a cloud-native Standalone (SA) core marks a key milestone in the evolution of our 5G architecture. This sets us on a path towards a fully automated network with the reliability, massive scale and flexibility required to deliver innovative 5G SA services to our consumer and enterprise customers.”
Pardeep Kohli, Mavenir’s President and CEO, said, “The Mavenir solution deployed with Deutsche Telekom in Germany, creates the foundation for the future introduction of 5G standalone enabling new applications and services to take advantage of 5G features such as low latency and network slicing.”
Key attributes of Mavenir’s solution include:
- Open Architecture: uses Telekom-defined hardware, a Kubernetes-based platform, and the automation framework of Deutsche Telekom.
- Network slicing support: with dedicated control and user plane network functions for meeting strict service level agreements.
- Cloud-native design: a fully containerized solution based on stateless microservice architecture that allows better resiliency and faster recovery in the event of network failures. It also enables the easy onboarding of users on Telekom’s Containers-as-a-Service (CaaS) that can be run on any public, private or hybrid cloud environment.
- Third-party vendor network function (NF) integration: integrated with multiple third-party vendors, including 4G and 5G access network and subscriber management functions.
- Converged architecture: Supports 4G, 5G non-standalone (NSA), and 5G standalone (SA) modes and enables all access technologies to run on a common cloud-native platform by Deutsche Telekom.
Mavenir’s Converged Packet Core solution is part of its cloud-native MAVcore portfolio built on an open architecture which offers easy scaling of applications and services, hardware decoupling, agility, portability and resilience.
Supporting Material:
- Case Study YouTube Video: GitOps Based Cloud Native 5GC Lifecycle Management – Based on Mavenir 5GC Implementation in Deutsche Telekom Technik with Das Schiff (T-CaaS @ TDG) Platform - Michal Sewera & Samy Nitsche, Deutsche Telekom
- White Paper: Move as Fast as You Can to the 5GC
A TCO Analysis of the Transition to a Converged 5G Core
- Solution Brief: Mavenir’s Converged Packet Core Solution
About Deutsche Telekom: https://www.telekom.com/companyprofile
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005103/en/
Contact information
Mavenir PR Contacts:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
Deutsche Telekom AG
Corporate Communications
Tel.: +49 228 181 – 49494
E-Mail: media@telekom.de
Further information for the media at:
www.telekom.com/media
www.telekom.com/photos
www.instagram.com/deutschetelekom
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses21.9.2023 16:00:00 CEST | Press release
Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to help prevent the spread of negatively charged viruses such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations. In development since 2022, the project has so far seen the completion of safety assessment utilizing intranasal administration at Altasciences’ preclinical site in Columbia, MO. A cardiovascular study was also completed at Altasciences’ preclinical facility in Scranton, PA. Bioanalytical sample analysis for the GLP studies is currently ongoing. “We
Nitek: End of the Road for Copycats21.9.2023 15:00:00 CEST | Press release
Nitek, Inc. (“Nitek”), a pioneering American company in UV LEDs, has announced that it filed a patent infringement lawsuit against Photon Wave Co., Ltd. (“Photon Wave”), a Korean UV LED manufacturer in the Eastern District of Texas. In the complaint, Nitek asserts that LED products of ams OSRAM, a German LED company, use Photon Wave’s infringing LEDs. Nitek also contends that Photon Wave has failed to cease selling infringing products, even after getting continuous warning notices of the patent infringement, and therefore Nitek is not only seeking a permanent injunction against the sales of infringing products but also pursuing 3 times damages for willful patent infringement. Nitek has previously successfully won its patent lawsuit against another international LED maker, and continues its enforcement against other infringers. Sensor Electronic Technology, Inc. (“SETi”), an affiliate of Nitek, has also obtained a permanent injunction for patent infringement against Bolb, Inc., a UV LED
Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution21.9.2023 15:00:00 CEST | Press release
Boomi™, the intelligent connectivity and automation leader, today announced the Boomi World Tour, a premiere series of exclusive, in-person events bringing together Boomi customers, prospects, and partners to hear directly from Boomi leadership, industry experts, and visionaries on how organizations can leave complexity behind and synchronize everything, everywhere, with AI-driven integration and automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230921479137/en/ Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution (Graphic: Business Wire) The Boomi World Tour is a series of 10 events over eight weeks, including three Partner Summits designed especially for Boomi partners, global systems integrators, and OEMs. The tour kicks off in Menlo Park, CA, October 3-4, 2023, where attendees will have opportunities to connect and learn throughout the tw
Hologic and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities21.9.2023 14:30:00 CEST | Press release
Hologic Inc. (Nasdaq: HOLX) and Bayer today announced an international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions. CEM is a highly sensitive and relatively low-cost breast imaging modality that combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.1 The partnership brings together the companies’ leading technologies (Hologic mammography gantries and Bayer CEM-approved injection systems) to enable the administration of contrast media during a mammography examination. With the new agreement, Bayer and Hologic aim to optimally support radiologists and their teams’ needs by providing a comprehensive product package along with the hands-on training needed to effectively implement CEM into their facility’s workflow. “Over the past several years, we’ve seen
ReNAgade Therapeutics Named to the 2023 Endpoints 1121.9.2023 14:00:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that it has been named as one of the Endpoints 11 companies of 2023, awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry. “To be included as one of the Endpoints 11 top private biotech companies is not only a great honor for our young company, but also recognition from the industry of what we’ve already accomplished in the past 18 months toward our aim of overcoming the current limitations of RNA medicines,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “The Company has continued to grow since our $300 million Series A financing round, building on our world-class, multidisciplinary team that is dedicated to innovating delivery technology and bringing an array of genomic medicine tools under one roof. We look forward to expanding the reach of RNA medicine beyond what was previously thought possible, beginning wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom